Virtual Library

Start Your Search

Andreia Chaves



Author of

  • +

    EP1.04 - Immuno-oncology (ID 194)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.04-39 - Is Body Mass Index a Prognostic Factor in Patients with Lung Cancer Treated with Immunotherapy?  (ID 82)

      08:00 - 18:00  |  Author(s): Andreia Chaves

      • Abstract
      • Slides

      Background

      Non-small cell lung cancer (NSCLC) is a prevalent disease with high mortality and poor response to traditional cytotoxic therapy. Immune checkpoint inhibitors (ICI) approvals were the landmark in the last years for the treatment of lung cancer. With these treatments, many patients with advanced disease are starting to see durable responses and longer survival rates.

      Several factors like obesity has been previously investigated for its role in cancer and promoting tumor growth, at least partially by inducing a chronic inflammatory state, but it’s unclear how it links to immunotherapy, where inflammation has been linked to treatment response,”

      High Body mass index (BMI) might have a positive impact in the outcomes of patients who are taking PD-1 or PD-L1 inhibitors, according to a recent study.

      In this study, we aim to determine if the body mass index (BMI) is a prognostic factor in patients treated with immunotherapy

      Method

      We retrospectively evaluated the outcomes of 30 patients with NSCLC confirmed histology, aged 18 years or older, treated with anti PD-1/PD-L1 from 2016 to 2018. BMI was stratified unto 2 groups: 1) normal and under-weighted (BMI < 25 kg/ m2) and 2) over-weighted and obese (BMI ≥ 25 kg/ m2). Simple descriptive statistics were created for all covariates.

      After statistical analyses with Kruskal-Wallis equality-of-populations rank test were related to progression free survival (PFS).

      Result

      A total of 30 lung cancer patients were enrolled in this study, divided by gender as 10 female-patients (33,33%) and 20 masculine-patients.(66,67%) The median age was 63 years (youngest 41-year-old and oldest 81 years old). According to histology 20 patients have adenocarcinoma (66,67 %) and 10 patients have squamous tumors (33,33%). Analyzing the mutational status, the majority was EGFR Wild type (WT).

      The majority of patients involved (43,33 %; 13 patients) were given immunotherapy in the third-line setting or beyond.

      More than half of patients had over-weighted and obese BMI (group 2 – 56,67% (n=17)).

      The median follow-up was 86 days (1 quartile 35 days and 3rd quartile 291 days (minimum 5 days, maximum 971 days).

      The median PFS in group 1 was 98 days (1 quartile 56 days and 3rd quartile 407 days (minimum 28 days, maximum 495 days) and in over-weighted and obese was 74 days (1quartil 26 days and 3rd quartile 127 days (minimum 5 days, maximum 971 days). There were no statistical differences in PFS (p= 0,249) between higher or lower BMI groups (group1 vs. group 2).

      Conclusion

      In this single institution cohort, BMI hadn’t a significant effect on outcomes of patients with lung cancer receiving anti PD-1/PD-L1 agents. As a critic to this evaluation we have that is for now a small group of patients and we think it is important to maintain studies in this field as the number of patients under this therapy increases.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.